If this latest treatment is ultimately successful, it would be “major step forward,” Petersen said.
“Cure is probably an overrated goal for Alzheimer’s disease but if we could delay the onset of the symptoms, slow the progression of the disease that would be huge for patients,” he added.
However, Petersen noted that right now only top-line results from the study have been released. Biogen and Eisai are expected to release the detailed results of the final analysis of the midstage trial at future conferences.
BAN2401 is one of two Alzheimer’s treatments Biogen and Eisai are pursuing. They are also developing a drug called aducanumab.
“They each have different ways of treating the disease. For now we intend to continue with both until we see exactly how they work,” Papadopoulos said.
Currently, 5.7 million Americans are living with Alzheimer’s and that number is expected to rise, according to the Alzheimer’s Association. By 2050, it’s projected to reach nearly 14 million people in the U.S.
— CNBC’s Tae Kim and Reuters contributed to this report.